Neurotech International (ASX:NTI) has announced positive results from its recently completed 28-day Good Laboratory Practice oral toxicology studies evaluating its lead drug candidate NTI164. …
Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies
May 5, 2025 Australian Biotech
Latest Video
New Stories
-
Medtech investment event unites investors and innovators to boost sector growth
May 5, 2025 - - Australian Biotech -
Mark Butler straight back to work as focus turns to issues and policy commitments
May 5, 2025 - - Latest News -
Neurotech says NTI164 shows positive tolerability in key preclinical toxicology studies
May 5, 2025 - - Australian Biotech -
Positive trial result for Immutep’s 'efti' in combination with MSD's anti-PD-1 therapy
May 5, 2025 - - Australian Biotech -
Arovella options advances Baylor College of technology to enhance iNKT cell platform
May 5, 2025 - - Australian Biotech -
FDA grants fast track designation for Alterity's ATH434 to treat multiple system atrophy
May 5, 2025 - - Australian Biotech -
New immune therapy treatment option for women diagnosed with advanced endometrial cancer
May 4, 2025 - - Latest News